Terapia con metformina e rischio di acidosi lattica

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR, American Diabetes Association (ADA), European Association for the Study of Diabetes (EASD) (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 35:1364–1379 Fujita Y, Inagaki N (2017) Metformin: new preparations and nonglycemic benefits. Curr Diabetes Rep 17(1):5 Bailey CJ, Turner RC, (1996) Metformin. N Engl J Med 334(9):574–579 Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA (1998) Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 338(4):265–266 Glucophage (metformin hydrochloride) and Glucophage XR (extended release) prescribing information. Bristol Myers Squibb, Bristol (2009) Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK (2014) Metformin in patients with type 2 diabetes and kidney disease: a systematic review. JAMA 312(24):2668–2675 Standard Italiani per cura del diabete mellito AMD–SID. http://www.standarditaliani.it/ Burnett RW, Covington AK, Fogh-Andersen N, Külpmann WR, Maas AH, Müller-Plathe O, Siggaard-Andersen O, Van Kessel AL, Wimberley PD, Zijlstra WG, International Federation of Clinical Chemistry (IFCC), Scientific Division. Committee on pH, Blood Gases and Electrolytes (1995) Approved IFCC recommendations on whole blood sampling, transport and storage for simultaneous determination of pH, blood gases and electrolytes. Eur J Clin Chem Clin Biochem 33(4):247–253 Salpeter SR, Greyber E, Pasternak GA, Salpeter EE (2010) Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis Cochrane Database Syst Rev 4:CD002967 DeFronzo R, Fleming GA, Chen K, Bicsak TA (2016) Metformin-associated lactic acidosis: current perspectives on causes and risk. Metabolism 65(2):20–29 Buse JB, DeFronzo RA, Rosenstock J, Kim T, Burns C, Skare S, Baron A, Fineman M (2016) The primary glucose-lowering effect of metformin resides in the gut, not the circulation: results from short-term pharmacokinetic and 12-week dose-ranging studies. Diabetes Care 39(2):198–205